Skip to main content
. 2014 Mar 4;3(3):e150. doi: 10.1038/mtna.2014.3

Figure 2.

Figure 2

DzT overcomes TKI resistance in EGFR T790M mutant cells. Gefitinib (1 μmol/l; a) or DzT- (100 nmol/l; b) treated cells were analyzed by immunoblotting with the indicated primary antibodies listed on the left. EGF (100 ng/ml) was added to CL1-5wt 15 min before cell lysis. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors.